The most telling comparison is the market cap of ALA - Arovella
I don’t understand the tech well enough to see the differences but they are at similar levels of cash flow and probably behind CHM on drug development, and they’re valuable at 100m+
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment, page-12
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable